Prostate, Bladder, Kidney and Testicular Cancers
Questions About Prostate, Bladder, Kidney and Testicular Cancers?
We’re here to help. Contact our Oncology Nurse Navigator, Dominique Srdanovic, RN, MA, OCN 203-276-CARE, Press 4
The Bennett Cancer Center offers treatment for prostate, bladder, kidney, testicular, ureteral, and urethral cancers. Our team works at a multidisciplinary level, bringing together urologists, medical oncologists, radiation oncologists, surgeons and other medical specialists to determine the most effective plan for your care. We use advanced diagnostic technology and the latest treatment options, including:
- The da Vinci® Robotic Surgery System
- Intensity-modulated, image-guided radiotherapy
- The CyberKnife® Radiosurgery System
These types of procedures aim to provide you with a high-precision, minimally invasive approach which means faster healing for you.
When we test you for prostate cancer, common screening tests include digital prostate examination and the prostate-specific antigen (PSA) blood test. We have the most sensitive PSA test available. Testicular tumors are complex and varied, and require careful evaluation to determine if the use of additional chemotherapy and radiation therapy is appropriate.
A Collaborative Approach to Your Genitourinary Care
Our team frequently gets together for the Genitourinary (GU) Tumor Conference to collectively make decisions about the best way to care for you. During this conference, individual patient cases like yours are reviewed so that by all the members of our team, including oncologic surgeons, medical oncologists, radiation oncologists, radiologists, pathologists, and urologists, giving each case a unique and personalized care plan.
We are also proud to offer state-of-the art immunotherapy to treat several GU malignancies. We are fully capable of treating prostate cancer patients with Sipileucel-T (Provenge), an immunotherapy generally used for advanced prostate cancer in those patients who are still relatively healthy. We also are well-versed in using immunotherapy to treat bladder and renal cell cancers. We have experience using many agents including nivolumab (Opdivo) and atezolizumab (Tecentriq).